2023-07-11 09:14:00
MERIDA. pharmaceutical company Sanofi introduced Dupilumabthe only biological medicine available in Mexico to treat moderate to severe cases of Atopic dermatitis (AD) in the pediatric populationfrom six months, and Asthma in children from six years.
Atopic Dermatitis and Asthma are type 2 inflammatory diseases, in which interleukin-4 and interleukin-13 are key drivers of allergic inflammation, the company said at a conference.
He mentioned that AD is a recurrent and chronic disease that is reflected through inflammation of the skin producing intense itching.
According to the International Study of Asthma and Allergy, in which Mexico participated with a population of 35,777 children and 41,399 adolescents, the increase in AD cases in children aged 6 to 7 years went from 6.6 to 7.8 percent, and in adolescents it rose from 5.8 to 6.7 percent.
For its part, asthma is chronic inflammation of the airway and bronchial hyperreactivity. It presents with wheezing, chest tightness, coughing, and shortness of breath. In children it is an important public health problem worldwide, where 6.0 percent of infants (5 to 9 years old) have the disease.
Some cases of AD and asthma are treated with low-potency steroidal anti-inflammatories at the lesion sites, but the side effects reduce the growth of the children and cause pressure problems, difficulty sleeping, and in some cases direct rejection of said medication.
In response to this, health specialists sought new medical alternatives such as Dupilumaband effective and safe immunomodulator for the improvement of pediatric patients.
LSN
1689071111
#Biological #medicine #children #asthma #atopic #dermatitis #announced
